The evaluation of cytotoxic drugs

Improvements in Survival and Clinical Benefit With Gemcitabine as First-Line Therapy for Patients With Advanced Pancreas Cancer: A Randomized Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023

Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas.

Annals of oncology : official journal of the European Society for Medical Oncology·2016

CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2016

Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001).

Cancer chemotherapy and pharmacology·2014

Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies.

European journal of cancer (Oxford, England : 1990)·2012

Telomerase and telomere inhibitors in preclinical development.

Expert opinion on investigational drugs·2005

Vinorelbine and low-dose cyclophosphamide as maintenance therapy in the treatment of Ewing sarcoma rationale for the international INTER-EWING-1 trial for Ewing sarcoma patients.

Cancer treatment reviews·2026

Is Cytoreductive surgery for unresectable colorectal liver metastases able to improve patient outcome? Results of a pilot prospective study.

Cancer treatment reviews·2026

Chondrosarcoma: A comprehensive review of tumor biology, clinical behavior, and therapeutic advances.

Cancer treatment reviews·2026

Pharmacological prevention of second primary cancers: From chemoprevention to precision cancer interception.

Cancer treatment reviews·2026

Understanding extrapulmonary neuroendocrine carcinomas: Survival, prognosis, and patient quality of life.

Cancer treatment reviews·2026

Comparative analysis of patient-derived organoids and patient-derived xenografts as avatar models for predicting response to anti-cancer therapy.

Cancer treatment reviews·2026

A synergistic cascade nanoreactor breaks bladder cancer chemoresistance: Synergizing cholesterol metabolism reprogramming with cGAS-STING-mediated metallotherapy.

Materials today. Bio·2026

Motivations, Decision-Making, and Barriers to Treatment Innovation Adoption: A Mixed-Methods Study of Addiction Treatment Executives.

Research square·2026

Mitochondrial Dysfunction in Ifosfamide-Induced Nephrotoxicity: Mechanisms and Possible Interventions.

European journal of pharmacology·2026

A direct comparison of butyrate, 4-phenylbutyrate, and β-hydroxybutyrate in an in vitro tumor therapy model.

Cancer treatment and research communications·2026

A Random Forest Analysis of Risk Factors and Trends in Substance Use Treatment Among Those Who Use Cannabis and Alcohol Together Before and After the COVID-19 Pandemic.

Substance use & misuse·2026

Emerging pharmacotherapies for chronic spontaneous urticaria: spotlight on BTK inhibitors.

Expert opinion on pharmacotherapy·2026

Related Experiment Videos

The evaluation of cytotoxic drugs

Related Concept Videos

Improvements in Survival and Clinical Benefit With Gemcitabine as First-Line Therapy for Patients With Advanced Pancreas Cancer: A Randomized Trial.

Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas.

CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.

Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001).

Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies.

Telomerase and telomere inhibitors in preclinical development.

Vinorelbine and low-dose cyclophosphamide as maintenance therapy in the treatment of Ewing sarcoma rationale for the international INTER-EWING-1 trial for Ewing sarcoma patients.

Is Cytoreductive surgery for unresectable colorectal liver metastases able to improve patient outcome? Results of a pilot prospective study.

Chondrosarcoma: A comprehensive review of tumor biology, clinical behavior, and therapeutic advances.

Pharmacological prevention of second primary cancers: From chemoprevention to precision cancer interception.

Understanding extrapulmonary neuroendocrine carcinomas: Survival, prognosis, and patient quality of life.

Comparative analysis of patient-derived organoids and patient-derived xenografts as avatar models for predicting response to anti-cancer therapy.

A synergistic cascade nanoreactor breaks bladder cancer chemoresistance: Synergizing cholesterol metabolism reprogramming with cGAS-STING-mediated metallotherapy.

Motivations, Decision-Making, and Barriers to Treatment Innovation Adoption: A Mixed-Methods Study of Addiction Treatment Executives.

Mitochondrial Dysfunction in Ifosfamide-Induced Nephrotoxicity: Mechanisms and Possible Interventions.

A direct comparison of butyrate, 4-phenylbutyrate, and β-hydroxybutyrate in an in vitro tumor therapy model.

A Random Forest Analysis of Risk Factors and Trends in Substance Use Treatment Among Those Who Use Cannabis and Alcohol Together Before and After the COVID-19 Pandemic.

Emerging pharmacotherapies for chronic spontaneous urticaria: spotlight on BTK inhibitors.

Related Experiment Videos

The evaluation of cytotoxic drugs

Related Concept Videos

Related Articles